Mechanistic target of rapamycin signaling pathway in effector T-cell (mTOR signaling pathway)

The mechanistic target of rapamycin (mTOR) signaling pathway in effector T-cells is a central integrator of environmental cues, including nutrient availability, growth factors, and antigen receptor engagement. In T cells, mTOR forms two main complexes: mTORC1 (sensitive to rapamycin, defined by Raptor) and mTORC2 (defined by Rictor), which regulate key cellular processes such as protein synthesis, cell cycle progression, metabolic reprogramming, and differentiation[1][2][3][4]. mTORC1 is particularly crucial for enabling T-cell activation, proliferation, and effector function, while both complexes together influence cell fate and memory formation[2][3]. Inhibition of mTOR, notably by drugs like rapamycin, can enhance CD8+ memory T-cell generation, but prolonged mTOR suppression can also impair the formation of effector-like T cells and dampen immune responses, which is relevant in contexts such as cancer immunotherapy and chronic viral infection[2][5]. Aberrant or unbalanced mTOR signaling in T-cells is implicated in multiple diseases, including cancer and autoimmune disorders[1][2]. Note: This query describes a signaling pathway, not a single molecular target or receptor. While mTOR itself (mechanistic target of rapamycin) is a molecular target and central kinase, the phrase "mTOR signaling pathway in effector T-cells" refers to a broader set of molecular events rather than a single molecule. As such, "is_target" is marked false and "is_incorrect" is true, because it names a pathway, not a canonical molecular target. For molecular targeting, the preferred canonical target should be "Mechanistic target of rapamycin (mTOR)", a serine/threonine kinase, rather than the pathway as a functional entity.

Other names

mTOR pathway in T cellsmTOR-T cell signaling

Kinase inhibition (drugs such as rapamycin inhibit mTOR kinase activity, affecting downstream cellular processes in T cells)